Viridian Therapeutics, Inc./DE Prepaid Expense and Other Assets, Current
Viridian Therapeutics, Inc./DE (VRDN) had Prepaid Expense and Other Assets, Current of $24.74 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-06
- 2026-06-30: Prepaid Expense and Other Assets, Current $24.74M.
- 2026-03-31: Prepaid Expense and Other Assets, Current $22.56M.
- 2025-12-31: Prepaid Expense and Other Assets, Current $19.58M.
- 2025-09-30: Prepaid Expense and Other Assets, Current $11.01M.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $24.74M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $22.56M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $19.58M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $11.01M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $15.39M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $20.61M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $20.88M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $14.10M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $10.30M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $13.53M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $9.01M 10-K · filed 2025-03-03 | |
| 2023-09-30 | $10.73M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $11.94M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $8.62M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $6.52M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $5.63M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $4.25M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $3.44M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $2.75M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $3.65M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $4.11M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $3.05M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $1.97M 10-K · filed 2022-03-11 | |
| 2020-09-30 | $1.84M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $1.69M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $2.23M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $2.89M 10-K · filed 2021-03-26 | $2.79M 10-K · filed 2020-03-13 |
| 2019-09-30 | $3.40M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $3.81M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $3.16M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $2.87M 10-K · filed 2020-03-13 | |
| 2018-09-30 | $3.84M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $3.76M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $3.44M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $2.97M 10-K · filed 2019-03-14 | |
| 2017-09-30 | $2.98M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $2.48M 10-Q · filed 2017-08-11 | |
| 2017-03-31 | $2.39M 10-Q · filed 2017-05-11 | |
| 2016-12-31 | $1.75M 10-K · filed 2018-03-15 | $160.00K 10-K · filed 2017-03-24 |
| 2016-09-30 | $366.00K 10-Q · filed 2016-10-26 | |
| 2016-06-30 | $594.00K 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $353.00K 10-Q · filed 2016-05-16 | |
| 2015-12-31 | $321.00K 10-K · filed 2017-03-24 | |
| 2015-09-30 | $570.00K 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $294.00K 10-Q · filed 2015-08-14 | |
| 2015-03-31 | $295.00K 10-Q · filed 2015-05-15 | |
| 2014-12-31 | $399.00K 10-K · filed 2016-03-21 | $349.00K 10-K · filed 2015-03-27 |
| 2014-09-30 | $434.90K 10-Q · filed 2014-11-14 | |
| 2014-06-30 | $468.88K 10-Q · filed 2014-08-14 | |
| 2013-12-31 | $445.00K 10-K · filed 2015-03-27 | $444.37K 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |